ClinicalTrials.gg
Active, not recruitingNCT07830849Updated Sep 21, 2026

Clinical Validation of Technologies for the Quantitative Characterization of Chronic Wounds

An interventional study of Quantitative Imaging-Based Chronic Wound Assessment in Chronic Wounds, sponsored by Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2026, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Chronic wounds are skin lesions that fail to heal within the expected timeframe and are frequently associated with underlying conditions such as diabetes, cardiovascular disease, obesity, and other chronic diseases. Their assessment is currently based primarily on clinical observation and standardized wound assessment tools. However, clinical evaluation may be affected by inter- and intra-clinician variability, potentially limiting the objectivity and reproducibility of wound characterization and monitoring.

This multicenter, interventional, non-profit pilot study aims to investigate the feasibility of using non-invasive imaging technologies to support the quantitative and objective characterization of chronic wounds. The study will evaluate the use of multimodal imaging, including ultrasound, high-resolution digital imaging, infrared thermography, and laser Doppler imaging, in patients with chronic wounds.

The primary hypothesis is that the use of complementary non-invasive imaging technologies may provide objective and reproducible information on wound characteristics and may show good agreement with standardized clinical wound assessment. The study will also explore whether the combination of information obtained through different imaging modalities may improve the characterization and monitoring of chronic wounds compared with clinical assessment alone.

Approximately 40 adult patients with chronic wounds, including pressure ulcers and venous ulcers, will be enrolled at participating clinical centers. Eligible participants will undergo repeated clinical assessments and non-invasive imaging examinations during the study period. Wound exudate may also be collected at predefined time points for exploratory analyses.

The primary objective is to assess the agreement and reproducibility between imaging-based wound characterization and standard clinical assessment. The study will also evaluate the performance of the individual imaging modalities and their combined use in characterizing relevant wound features.

Exploratory objectives include investigating the potential of the collected data to support the development of quantitative and predictive approaches for wound assessment and monitoring. The study will also explore the relationship between imaging-derived parameters and biological information obtained from wound exudate.

The study is intended as a pilot investigation to generate preliminary evidence on the feasibility and potential clinical value of multimodal imaging for the objective assessment of chronic wounds. The results may provide a basis for future clinical validation studies and for the development of innovative approaches to support chronic wound management.

02

Conditions studied

  • Chronic Wounds
03

In context

Lead sponsor

Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both sexes aged over 18 years;
  • Patients with a chronic venous or pressure wound. In the case of venous wounds, the diagnosis must be confirmed by Doppler examination. The wound must have been present for at least 6 weeks and show less than 50% reduction in wound area after 30 days of standard treatment;
  • Patients with chronic wounds up to Grade III.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding;
  • Patients with signs of systemic infection (MEWS > 0);
  • Patients with active neoplastic disease, hematological disorders affecting coagulation, or systemic inflammatory diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus);
  • Individuals unable to manage their own interests or provide valid , even if represented by a legal representative who has provided consent to participation;
  • Ankle-Brachial Index (ABI) \< 0.8;
  • (BMI) > 40.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Multimodal Non-Invasive Imaging Assessment

    Diagnostic Test: Quantitative Imaging-Based Chronic Wound Assessment

Interventions

  • Diagnostic testQuantitative Imaging-Based Chronic Wound Assessment

    The intervention consists of a multimodal, non-invasive imaging approach for the quantitative assessment of chronic wounds. Participants will undergo wound imaging using complementary imaging modalities, including ultrasound, high-resolution digital imaging, infrared thermography, and laser Doppler imaging. The acquired data will be analyzed to obtain quantitative information on relevant wound characteristics and to support standardized wound assessment. Imaging-based findings will be compared with conventional clinical wound assessment to evaluate their concordance, reproducibility, and potential diagnostic value. Repeated assessments will be performed during the study to explore the potential of the approach for monitoring wound evolution over time.

06

What researchers measure

Primary outcomes

  1. Inter-Rater Agreement of Total BWAT Score Among Clinicians

    Agreement among clinicians in the assessment of chronic wound characteristics will be evaluated using the Bates-Jensen Wound Assessment Tool (BWAT). The total BWAT score, ranging from 13 to 65, will be treated as a continuous variable. Agreement among clinical evaluators will be assessed using the Intraclass Correlation Coefficient (ICC), with 95% confidence intervals, at each predefined assessment time point.

    Time frame: Days 1, 7, 14, and 21

  2. Agreement Between Individual Imaging Technologies and Clinical Assessment of BWAT Items

    Each of the four imaging technologies-ultrasound, high-resolution digital imaging, infrared thermography, and laser Doppler imaging-will be evaluated separately for its ability to characterize individual wound features corresponding to items of the Bates-Jensen Wound Assessment Tool (BWAT). For each imaging technology, the imaging-based assessment of individual BWAT items will be compared with the corresponding clinical assessment. Agreement will be evaluated separately for each BWAT item and at each predefined assessment time point using the Overall Coefficient of Concordance (OCCC). Diagnostic performance will additionally be assessed, as applicable, using sensitivity, specificity, overall accuracy, receiver operating characteristic (ROC) curves and area under the ROC curve (AUC), and confusion matrices.

    Time frame: Days 1, 7, 14, and 21

  3. Agreement Between Individual Imaging Technologies and Clinical Total BWAT Score

    Each of the four imaging technologies-ultrasound, high-resolution digital imaging, infrared thermography, and laser Doppler imaging-will be evaluated separately with respect to the total Bates-Jensen Wound Assessment Tool (BWAT) score obtained by clinical assessment. The total BWAT score ranges from 13 to 65 and will be treated as a continuous variable. For each imaging technology, the total BWAT score derived from the imaging-based assessment will be compared with the total BWAT score obtained by standard clinical assessment. Agreement between imaging-based and clinical assessments will be evaluated using the Intraclass Correlation Coefficient (ICC), with 95% confidence intervals, at each predefined assessment time point. Diagnostic performance measures may additionally be calculated, as applicable, to characterize the ability of each imaging technology to reproduce the clinically assessed total BWAT score.

    Time frame: Days 1, 7, 14, and 21

07

Study locations

1 site
  • Scuola Superiore Sant'Anna, The BioRobotics Institute
    Pontedera, Pisa 56025, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2026
First posted
Sep 21, 2026
StartActual
Apr 15, 2026
Primary completionEst.
Sep 24, 2026
CompletionEst.
Sep 24, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07830849
Lead sponsor
Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna
Collaborators
Auxilium Vitae Volterra, Centro di Riabilitazione Motoria INAIL, Azienda Ospedaliero, Universitaria Pisana
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Apr 15, 2026
Primary completion
Sep 24, 2026 (estimated)
Completion
Sep 24, 2026 (estimated)
Last update
Sep 21, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion